Insulet Corp is a healthcare company specializing in the development and manufacturing of innovative insulin delivery systems for individuals with diabetes. The company is best known for its Omnipod Insulin Management System, a tubeless, waterproof device that allows users to deliver insulin discreetly and conveniently without the need for traditional syringes or infusion sets. Insulet is committed to enhancing the quality of life for diabetes patients by providing advanced technology solutions that simplify insulin management, improve glycemic control, and promote independence in self-care. Through ongoing research and development, Insulet aims to lead the way in diabetes management innovation. Read More
Growth is oxygen.
But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
Curious about the top performers within the S&P500 index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top S&P500 gainers and losers in today's session.
Quality compounders are flywheels.
Said differently, they’re businesses that generate heaps of profits and consistently reinvest them to produce even more profits.
Rinse and repeat.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today hosted its 2025 Investor Day at the Company’s global headquarters in Acton, Massachusetts.
Insulet Corp (PODD) offers strong growth and profitability at a reasonable valuation. Its solid financial health makes it a top affordable growth stock.
Since May 2025, Insulet has been in a holding pattern, posting a small return of 3% while floating around $335.74. The stock also fell short of the S&P 500’s 11.9% gain during that period.
Discover how Insulet Corp (PODD) combines strong technical uptrends with high-growth fundamentals, presenting a potential market leader for growth investors.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth.
This has capped returns as the industry’s six-month gain of 9.8% has lagged the S&P 500’s 17.2% climb.
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Thursday. Stay informed about the latest market trends.
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers.
Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 29.9% year on year to $706.3 million. On top of that, next quarter’s revenue guidance ($767.8 million at the midpoint) was surprisingly good and 5.1% above what analysts were expecting. Its non-GAAP profit of $1.24 per share was 8.1% above analysts’ consensus estimates.
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended September 30, 2025.
